Precision Wealth Strategies LLC Purchases Shares of 163,675 Niagen Bioscience, Inc. $NAGE

Precision Wealth Strategies LLC purchased a new stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) during the third quarter, HoldingsChannel.com reports. The fund purchased 163,675 shares of the company’s stock, valued at approximately $1,527,000.

Other large investors have also modified their holdings of the company. Silverberg Bernstein Capital Management LLC bought a new position in Niagen Bioscience in the 3rd quarter worth $1,169,000. BSW Wealth Partners acquired a new stake in shares of Niagen Bioscience in the third quarter valued at about $793,000. Finally, CWM LLC bought a new position in shares of Niagen Bioscience in the third quarter worth about $246,000. 15.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their price objective on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Wall Street Zen downgraded shares of Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Niagen Bioscience has a consensus rating of “Moderate Buy” and an average price target of $14.28.

Insider Transactions at Niagen Bioscience

In other Niagen Bioscience news, CFO Ozan Pamir acquired 4,465 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was bought at an average price of $6.81 per share, for a total transaction of $30,406.65. Following the purchase, the chief financial officer owned 7,372 shares in the company, valued at $50,203.32. This represents a 153.59% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 9.39% of the stock is owned by company insiders.

Niagen Bioscience Trading Up 1.5%

Shares of NAGE stock opened at $6.61 on Friday. Niagen Bioscience, Inc. has a 12 month low of $5.16 and a 12 month high of $14.69. The company has a market capitalization of $527.54 million, a P/E ratio of 27.54 and a beta of 2.31. The stock has a 50 day moving average of $6.87 and a two-hundred day moving average of $9.19.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $33.99 million for the quarter, compared to analysts’ expectations of $31.30 million. Niagen Bioscience had a return on equity of 24.13% and a net margin of 16.38%.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.